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Alternative promoter usage and mRNA splicing pathways for parathyroid
hormone-related protein in normal tissues and tumours
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Summary The parathyroid hormone-related protein (PTHrP) gene consists of nine exons and allows the
production of multiple PTHrP mRNA species via the use of three promoters and 5' and 3' alternative splicing;
as a result of 3' alternative splicing one of three protein isoforms may be produced. This organisation has
potential for tissue-specific splicing patterns. We examined PTHrP mRNA expression and splicing patterns in
a series of tumours and normal tissues. using the sensitive reverse transcription-polymerase chain reaction
(RT-PCR) technique. Use of promoter 3 and mRNA specifying the 141 amino acid PTHrP isoform were
detected in all samples. Transcripts encoding the 139 amino acid isoform were detected in all but two samples.
Use of promoters I and 2 was less widespread as was detection of mRNA encoding the 173 amino acid
isoform. While different PTHrP splicing patterns were observed between tumours, no tissue- or tumour-specific
transcripts were detected. In comparing normal and tumour tissue from the same patient, an increase in the
number of promoters utilised was observed in the tumour tissue. Furthermore, mRNA for the PTH/PTHrP
receptor was detected in all samples, thus the PTHrP produced by these tumours may potentially act in an
autocrine or paracrine fashion.
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Parathyroid hormone-related protein (PTHrP) was initially
discovered as a tumour product involved in malignancy-
associated hypercalcaemia and has since been identified in a
wide range of tumours as well as in normal tissues (Martin et
al., 1991; Moseley and Gillespie, 1992). The protein exhibits
sufficient N-terminal homology with PTH to interact with the
PTH receptor, accounting for its PTH-like actions in pro-
moting hypercalcaemia (Abou-Samra et al., 1992). The
human PTHIPTHrP receptor has been cloned from kidney
and osteoblast-like osteosarcoma cell cDNA libraries and
was found to be a member of a family of seven transmem-
brane domain, G-protein-linked receptors (Schipani et al.,
1993). The remainder of the PTHrP sequence diverges from
that of PTH and possesses non-PTH-like actions, including
roles in placental calcium transport (Rodda et al., 1988),
inhibition of osteoclastic bone resorption in vitro (Fenton et
al., 1991) and cell growth andbor differentiation (Henderson
et al., 1991).
The human PTHrP gene consists of nine exons. of which
only two are present in all PTHrP transcripts: exon V,
encoding the prepro region of the protein, and exon VI,
which encodes the majority of the coding region for the
mature protein up to residue 139, where a splice donor site is
located. Readthrough of exon VI to exon VII introduces a
stop codon and produces mRNA for the 139 amino acid
isoform, while splicing of exon VI to exon VIII or IX results
in mRNA specifying the 173 and 141 amino acid isoforms
respectively (Suva et al., 1987; Mangin et al., 1988a,b, 1989;
Thiede et al., 1988; Yasuda et al., 1989). Thus, alternative 3'
splicing allows the production of mRNA specifying three
isofoms of PTHrP which differ in their C-terminal regions.
Three promoters have been identified in the gene: two TATA
promoters, 5' to exons I and IV (P1 and P3 respectively)
(Thiede et al.. 1988; Mangin et al., 1989, 1990; Suva et al..
1989: Yasuda et al.. 1989), and a GC-rich promoter, 5' to
exon III (P2) (Vasavada et al.. 1993). In addition, exon II
may be included in or excluded from transcripts originating
from promoter 1 (Mangin et al.. 1990; Glatz et al., 1994), or
exon I may be spliced directly to exon V (Glatz et al., 1994).
We and others have demonstrated in cell lines that more than
one promoter may be utilised and alternative splicing events
occur (Mangin et al.. 1990; Southby et al., 1993; Vasavada et
al., 1993; Brandt et al., 1994; Glatz et al., 1994). The
presence of three promoters and 5' and 3' alternative splicing
suggests that PTHrP expression may be differentially
regulated by growth factors during development or in a
tissue-specific manner. It has been suggested that tissue-
specific splicing of PTHrP mRNA does occur (Mangin et al.,
1989; Campos et al., 1992; Brandt et al., 1994), however
these studies utilised only cell lines (Brandt et al., 1994) or a
small number of primary tumours (Mangin et al., 1989;
Campos et al., 1992). To investigate whether PTHrP mRNA
is alternatively spliced in a tissue-specific manner we have
examined the PTHrP mRNA splicing patterns in a series of
tumours and normal tissues, using the reverse transcrip-
tion-polymerase chain reaction (RT-PCR) technique with
PTrHrP exon-specific pnrmers. We found that while the
tumours exhibited different splicing patterns, these differences
were not tumour type-specific. Since PTHrP may have local
actions, as well as its hypercalcaemic actions observed in
malignancy-associated hypercalcaemia, we also examined the
tissue and tumour samples for mRNA encoding the PTH/
PTHrP receptor.
Materials and methods
Tumour samples
Tumours, and normal tissue where available, were collected
at biopsy or surgery from patients attending the Heidelberg
Repatriation Hospital or St. Vincent's Hospital, in the nor-
mal course of their management. The tissues were immediate-
ly placed on dry ice and stored at - 70°C. The tumour
samples included 13 breast tumours [all infiltrating ductal
carcinomas, with three tumours also containing a ductal
carcinoma in situ component (B1, B4, B 1)], five renal cor-
tical carcinomas (R 1-R5) and one renal carcinoma metas-
tasis to lung (R6), 13 lung tumours [eight squamous cell
carcinomas (LI-L8), two large cell carcinomas ([9, LIO),
one small cell carcinoma (Lll) and two adenomas (L12,
L13)], one oesophageal squamous cell carcinoma (E), one
hepatoma (H) and five parathyroid samples [one hyperplasia
(PT1) and four adenomas (PT2-PT5)]. Normal tissue
included two renal and four lung samples adjacent to the
tumour sample and one thyroid sample (T) which was
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obtained in the course of removal of the parathyroid gland.
The calcium status (normo-. hypo- or hypercalcaemic) of the
patients from which biopsies were obtained is not known.
RVA extraction, cDNA sy nthesis andpolt merase chain
reaction (PCR}
Total RNA was extracted from the tissues by the guan-
idinium thiocyanate-phenol-chloroform method (Chomczyn-
ski and Sacchi, 1987). An aliquot of 5 Lg of total RNA was
reverse transcribed from an oligo (dT) primer using 0.5 gg of
oligo (dT) primer (Promega. WI. USA). 15 units of avian
myeloblastosis virus reverse transcriptase (Promega). 5 ptl of
5 x reverse transcription buffer. 0.25 mM each dATP. dCTP.
dGTP and dTTP (Pharmacia. Uppsala. Sweden). 10 mM
dithiothreitol and sterile distilled water to a total volume of
25!tl.
One twenty-fifth of the reverse transcription (RT) reaction
was used per PCR in a 20 fL reaction mixture containing
50 pmol of each primer. 25 gm each dATP, dGTP. dCTP and
dTTP. 2 gl of 10 x reaction buffer. 1 unit of Taq DNA
polymerase (Boehringer Mannheim. Mannheim, Germany)
and sterile distilled water and overlaid with 50ILI of paraffin
oil. Amplification was performed in a Perkin Elmer DNA
thermal cycler 480. with 40 cycles of denaturation at 95'C for
30 s. annealing at 55'C for 30 s and extension at 72'C for
1 mmn. PCR products were resolved on a 2% (w v) agarose
gel, transferred to Hybond-N membrane (Amersham, Buck-
inghamshire. UK) and hybridised with a 32P-labelled (Amer-
sham) oligonucleotide probe in order to confirm the
specificity of the reaction. All negative control reactions (e.g.
primers without DNA. PCR on RNA which had not been
reverse transcribed) were negative by gel and Southern hyb-
ridisation.
Oligonucleotides utilised for PCR and authentication of
PCR products were synthesised on an Applied Biosystems
(CA. USA) DNA synthesiser model 381A. PTHrP oligonuc-
leotides were: obrf 15.8 [5'-TGAAGGAAGAATCGTCGCC-
GTAAATCTTGGATGGAC-3' antisense strand-specific to
exon VI. nucleotides + 147 to + 182 from the start of trans-
lation with respect to cDNA sequence (Suva et al.. 1987)]:
obrf 15.83 [5'-GTTGGAGTAGCCGGTTGCTA-3'. sense
strand-specific to exon IV, nucleotides -211 to - 192 from
the start of translation with respect to genomic sequence
(Suva et al.t 1989)]: obrf 15.84 [5'-CGGTGTTCCTGCTGA-
GCTA-3' sense strand-specific to exon V, nucleotides + 35 to
+ 53 from the start of translation with respect to cDNA
sequence (Suva et al., 1987)]; obrf 15.89 [5'-TGCGATCAG-
ATGGTGAAGGA-3'. antisense strand-specific to exon VI.
nucleotides + 176 to + 195 from the start of translation with
respect to cDNA sequence (Suva et al., 1987)]; obrf 15.90
[5'-CACAATCGATAGAGATAC-3'. antisense strand-speci-
fic to exon VII. nucleotides +620 to +637 from the start of
translation with respect to cDNA sequence (Yasuda et al..
1989)]; obrf 15.91 [5'-GAGATCATTAGTTGCATATG-3'.
antisense strand-specific to exon VIII, nucleotides + 580 to
+ 599 from the start of translation with respect to cDNA
sequence (Yasuda et al., 1989)]; obrf 15.92 [5'-CAGAATCC-
TGCAATATGTCC-3'. antisense strand-specific to exon IX,
nucleotides + 558 to + 577 from the start of translation with
respect to cDNA sequence (Yasuda et al.. 1989)]; obrf 15.93
[5'-AGGTACCTGCT-TCTAATA-3'. sense strand-specific
to exon I. nucleotides -3210 to -3191 from the start of
translation with respect to genomic sequence (Mangin et al..
1990)]; obrf 15.95 [5'-TTCTCCGGCAGGTTTG-3'. sense
strand-specific for promoter 2 transcripts. nucleotides -783
to -768 from the start of translation with respect to
genomic sequence (Vasavada et al.. 1993)]. Oligonucleotides
specific for the human PTH PTHrP receptor were obrf 15.112
[5'-CCTCTTTGGCGTCCACTACATTG-3'. sense strand-
specific. nucleotides + 1273 to + 1295 (Schipani et al.. 1993)]:
obrf 15.113 [5'-TTGAGGAACCCATCGTCCTTG-3'. anti-
sense strand-specific. nucleotides + 1702 to + 1722 (Schipani
et al., 1993)] and the detection oligonucleotide obrf 15.114
[5'-GGCAAGTCCAGATGCACTATGAG-3'. sense strand-
specific, nucleotides + 1337 to + 1360 (Schipani et al., 1993)].
Oligonucleotides used to amplify a 414 bp fragment of gly-
ceraldehyde-3-phosphate dehydrogenase (GAPDH) were:
GAPDH-4 [5'-CATGGAGAAGGCTGGGGCTC-3'. nucleo-
tides 306-325 (Tso et al.. 1985)] and GAPDH-3 [5'-
CACTGACACGTTGGCAGTGG-3'. nucleotides 701-720
(Tso et al.. 1985)] and products were verifed with an internal
sense strand oligonucleotide, GAPDH-1 [5'-GCTGTGGG-
CAAGGTCATCCC-3'. nucleotides 640-659 (Tso et al.,
1985)]. Oligonucleotides for GAPDH amplification were
designed to different exons [GAPDH-4 across exons 5 and 6
and GAPDH-3 to exon 8 (Ercolani et al.. 1988)]. allowing for
the detection of GAPDH mRNA only.
Results
The sensitive RT- PCR method was used to determine
PTHrP promoter usage and mRNA splicing patterns in a
series of tumour and normal tissues. Figure 1 shows the
organisation of the human PTHrP gene. its splicing path-
ways and the exon-specific primers used for PCR. Total
RNA was extracted from 39 tumours and seven samples of
normal tissue and subjected to RT-PCR with the PTHrP
primers and primers specific for the PTH PTHrP receptor. In
addition. RT-PCR with GAPDH primers was performed as
a control for the quality of the extracted RNA and for the
reverse transcnption reaction. Since the aim of this study was
purely qualitative. i.e. to determine which splicing patterns
were utilised. PCR was carried out under saturating. non-
quantitative. conditions with the PTHrP- and PTH PTHrP
receptor-specific primers. The majority of PCR products were
clearly visible after 30 cycles of PCR. however, in order to
ensure detection of all the splicing patterns utilised, the PCRs
were conducted at 40 cycles, which had been determined
previously to be saturating for the PTHrP primers.
Amplification of GAPDH cDNA was carried out at 30 cycles
which was found to be saturating for the GAPDH primers.
PCR was initially performed using primers to the two
invariant exons of PTHrP mRNA, exons V and VI (Figure
1), in order to assess PTHrP mRNA production (Figure 2).
A band of the appropriate size (161 bp) was observed for
each sample, which hybridised with an internal PTHrP
oligonucleotide (obrf 15.8), confirming that the PCR prod-
ucts were the results of specific amplification of PTHrP
mRNA. Thus all of the tumour and normal tissues examined
expressed PTHrP mRNA (Figure 2).
To address which of the PTHrP isoforms the tumours were
capable of producing (i.e. 139. 141 or 173 amino acid
isoforms), the 3' alternative splicing patterns were inves-
tigated by amplifying between the common exon V and the
alternative exons VII. VIII and IX (Figure 1). All of the
breast tumours studied used each of the three 3' splicing
pathways (Figure 2a. Bi -B13) and thus expressed mRNA
specifying each of the three PTHrP isoforms. A similar pat-
tern of 3' splicing was observed with the renal samples
(Figure 2b). Splicing of exon VI to each of the three alterna-
tive 3' exons occurred in both the normal renal tissue (NI
and N2) and the tumour samples (RI -R6). Three of the
normal lung samples (Figure 2c, NI -N3) and the 13 lung
tumours (LI -L13) utilised the exon VII and exon IX splicing
pathways. The fourth normal lung sample (N4) used the
exon IX but not the exon VII splicing pathway. Exon VI was
spliced to exon VIII in only three of the normal samples (NI.
N3, N4) and nine of the tumours (Figure 2c. LI. L2, L3, L5.
L6, L9, LIO. L12 and L13). The three splicing pathways were
utilised in the oesophageal squamous cell carcinoma (E), the
hepatoma (H) and three of the five parathyroid samples
(PTI-PT3). but exon VIII-containing mRNA was not
detected in the normal thyroid tissue (T) nor in two of the
five parathyroid samples (PT4 and PT5; Figure 2d). Thus, all
tissues examined contained mRNA specifying the 141 amino
acid isoform of PTHrP and all but two samples (lung N4 and
PT5) contained mRNA encoding the 139 amino acid
isoform, while the utilisation of the exon VIII splicing pat-
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obrf 15.83
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obrf 15.89
obrf 15.90
PCR primer combination Transcripts detected Exons Size of product (bp)
obrf 15.84-obrf 15.89 All transcripts V-VI 161
obrf 15.84-obrf 15.90 139 aa isoform V-V-VII 603
obrf 15.84-obrf 15.91 173 aa isoform V-VIVIII 565
obrf 15.84-obrf 15.92 141 aa isoform V-VI-IX 543
obrf 15.93-obrf 15.89 P1 transcripts HHI-4-4V-VI 739
tI-4l-V-VI 646
I-V-VI 406
obrf 15.95-obrf 15.89 P2 transcripts lI-V-VI 468
obrf 15.83-obrf 15.89 P3 transcripts IV-V-VI 242
Fgre 1 Diagrammatic representation of the genomic organisation of the PTHrP gene. The coding regions and the untranslated
sequences are indicated by the closed and open boxes respectively. Indicated above the map are the three promoters. P1 (5' to exon
1) and P3 (5' to exon IV) are TATA promoters and P2 (5' to exon III) is a GC-nrch promoter. Potential splicing events are shown.
The arrows below the map indicate the orientation and location of the primers used for RT-PCR analysis of PTHrP transcripts
and the antisense oligonucleotide used to detect PTHrP products (obrf 15.8) is represented below exon VI. Also shown are the PCR
primer combinations used for Figure 2, the transcripts they detect along with the predicted isoform produced, the exonic sequences
contained in the amplified product and the size of the PCR product in bp.
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Figue 2 PCR analysis of PTHrP mRNA splicing patterns and for the detection of PTH/PTHrP receptor mRNA. PCR
amplification of PTHrP cDNA was performed between the exons indicated, using the primers shown in Figure 1. PCR
amplification of PTH/THrP receptor cDNA was carried out using primers obrf 15.112 and obrf 15.113 and amplification of
GAPDH cDNA with primers GAPDH-3 and GAPDH-4. PCR products were resolved on a 2% (w/v) agarose gel, transferred to a
nylon membrane and hybridised with an internal oligonucleotide; obrf 15.8 (PTHrP), obrf 15.114 (PTH/PrHrP receptor) or
GAPDH-1. PCR analysis of PTHrP mRNA splicing patterns and PTH/PTHrP receptor mRNA was conducted on (a) 13 breast
tumours (Bl-B13), (b) two normal renal samples (NI and N2) and six renal tumours (RI-R6), (c) four normal lung samples
(NI -N4) and 13 lung tumours (LI -L13), (d) an oesophageal squamous cell carcinoma (E), hepatoma (H), normal thyroid (T), one
parathyroid hyperplasia and four parathyroid adenomas (PTI-PT5). The autoradiographs are at different exposure times (2-16 h)
in order to optimise the visibility of the bands of weaker intensity and the reactions were performed twice with similar results.
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atern and hence the production of the 173 isoform was more
variable.
To differentiate between the use of the PTHrP promoters.
PCR was carried out using primers to the alternative 5'
exons, specific to transcripts derived from each of the pro-
moters (P1, P2 and P3). and the common exon VI (Figure 1).
PCR amplification between the primers specific for exon I
(obrf 15.93) and exon VI (obrf 15.89) detects promoter 1-
specific transcripts and may result in amplification of three
different products which indicate alternative splicing of exons
II and III in the primary transcript. The three products
represent (a) splicing of exons I. II, III, V and VI (739 bp),
(b) splicing of exons I. III. V and VI (with the exclusion of
exon II; 646 bp) and (c) splicing of exon I directly to exons V
and VI (406 bp) (Glatz et al.. 1994). We did not detect in any
of the normal tissues or tumours any products equivalent to
the 406 bp fragment resulting from splicing of exons I-V.
Exon IV-containing transcripts are the result exclusively of
P3 activity, thus exon I- and IV-containing transcripts are
exquisite markers for P1 and P3 activity respectively. P2
transcripts are initiated 11 nucleotides 5' to the splice accep-
tor site of exon III (Vasavada et al., 1993). For detection of
P2 activity, the 5' primer was synthesised to this region in
order to distinguish between P2 transcripts and those con-
taining exon III as a result of initiation from P1 and subse-
quent splicing to exon III (Glatz et al., 1994). Thus
amplification between exons I. III and IV and exon VI
allowed the usage of P1. P2 and P3 respectively. to be
determined (Glatz et al., 1994).
Promoter 1 transcripts were detected in seven of the 13
breast tumours, as determined by amplification between
exons I and VI (Figure 2a). Two products were identified in
four of these tumours (B1. B4, B5 and B8), the larger prod-
uct (739 bp) corresponding to P1 transcripts containing exon
II and the smaller (646 bp) representing P1 transcripts in
which exon II has been spliced out; the products are not
resolved on this gel. The other three tumours (Figure 2a, B7,
B10 and B12) in which P1 was active appeared to use only
the I-II-III-V-VI splicing pathway. One of the two nor-
mal renal samples (N1) and all of the six renal tumours
(RI - R6) contained P1 transcripts (Figure 2b), with the nor-
mal tissue and three of the tumours (R3-R5) utilising the
I-II-III-V-VI splicing pathway only. Two renal tumours
(RI and R6) appeared to produce P1 transcripts both with
and without exon II and the remaining tumour (R2) pro-
duced only P1 transcripts in which exon II had been spliced
out. P1 transcripts were present in one sample of normal
lung tissue (NI) and in six of the lung tumours (Figure 2c).
P1 transcripts both with and without exon II were identified
in the normal tissue (NI) and three of the lung tumours (L5,
L6 and L9), while P1 only transcripts containing exon II
were detected in the other three lung tumours (LI, L2 and
LI 1). P1 transcripts containing exon II were identified in the
oesophageal tumour (E), the hepatoma (H) and one of the
parathyroid samples (PT1; Figure 2d). The other parathyroid
sample in which P1 was active (PT3) contained P1 transcripts
both with and without exon II (Figure 2d).
PCR was performed between exons III and VI to deter-
mine usage of the GC-rich promoter. Promoter 2-specific
transcripts were detected in eight of the 13 breast tumours
(Figure 2a) and all of the renal samples except one tumour
sample (Figure 2b, R4). P2-initiated transcripts were not
detected in the normal lung tissues but were present in five of
the lung tumours (L3. L5, L6. L9 and LI 1); four of the lung
tumours (L5. L6. L9 and L11) contained both P1- and
P2-initiated transcripts (Figure 2c). The oesophageal tumour
(E) and two of the five parathyroid samples (PT2, PT3) also
contained P2 transcripts (Figure 2d).
In contrast to the more restricted utilisation of P1 and P2,
P3-initiated transcripts were detected in all of the tissue
samples. While many of the samples utilised all three pro-
moters, there were examples of use of P1 but not P2 and vice
versa.
Overall, the use of P3 and splicing to exon IX appeared to
be common to all normal and tumour tissues and all except
PTHrP aIrnatve mRNA splicng
J Southby etal
two samples used the exon VII splicing pathway but there
was differential use of the alternative exon VIII and of the
two upstream promoters P1 and P2. Each group of tumours
exhibited an array of splicing patterns and there did not
appear to be a splicing preference particular to one tissue or
tumour type.
For the two normal kidney samples and three of the four
normal lung samples there was also tumour tissue from the
same patient (renal: NI R2. N2 R3: lung: NI L9. N2 L2.
N4 L6). The same splicing patterns were observed in the
normal and tumorous renal tissues except for the use of P1 in
one pair: P1 was not active in one normal renal sample (N2)
but P1 transcripts were detected in the tumour counterpart
(R3; Figure 2b). In comparing the normal and tumour lung
samples (Figure 2c), two normal lung samples used P1 and
P3 (Ni) or P3 only (N4) while their tumour counterparts
utilised all three promoters (L9 and L6 respectively). Pro-
moter 3 only was active in the third normal lung sample (N2)
while P1 and P3 were active in the tumour (L2). One normal
sample (N4) lacked exon VII-containing mRNA and another
(N2) lacked exon VIII-containing mRNA while the corres-
ponding tumours (L6 and L2) utilised all three 3' splicing
pathways. This would result in the two lung tumour samples.
L2 and L6, producing each of the three PTHrP protein
isoforms, while their corresponding normal samples. N2 and
N4, are predicted to only produce the 139 and 141 or the 173
and 141 amino acid isoforms respectively.
In addition, the tissue and tumour samples were examined
for the presence of PTH/PTHrP receptor mRNA. Amplifica-
tion with two receptor-specific primers detected mRNA for
the PTH/PTHrP receptor in all of the samples (Figure 2).
RT-PCR with GAPDH primers was performed as a con-
trol for the quality of the extracted RNA and for the reverse
transcription reaction. Each of the tissue and tumour samples
displayed a band on PCR with the GAPDH primers which
hybridised with the internal GAPDH oligonucleotide.
GAPDH-1 (Figure 2).
Discussion
The human PTHrP gene has a complex organisation. with
nine exons. three promoters and multiple splicing pathways
(Martin et al., 1991; Moseley and Gillespie, 1992). Initial
studies have raised the possibility of tissue-specific splicing of
PTHrP transcripts (Mangin et al.. 1989; Brandt et al.. 1992,
1994; Campos et al., 1992). however these studies were
limited by the number of samples analysed or failure to
examine the use of all three promoters at a time when the
complete exonic structure had not been resolved; the GC-rich
promoter, P2, had not been identified. Mangin et al. (1989)
assessed the PTHrP mRNA splicing pathways of four human
tumours of different types and found that the tumours
displayed different 3' splicing pathways, leading to the sug-
gestion that the PTHrP mRNA splicing patterns were
tumour-specific. Campos et al. (1992) examined the use of
the two TATA promoters (P1 and P3) in 17 neoplastic and
11 non-neoplastic tissues, finding that most of the samples
which expressed PTHrP utilised both P1 and P3. However
utilisation of the GC-rich promoter was not addressed.
Vasavada et al. (1993) in examining the relative use of the
three promoters by a number of cell lines and tissues found
P2 and P3 to be widely utilised with use of P1 more
restricted. Brandt et al. (1994) investigated both PTHrP pro-
moter usage and 3' splicing pathways of seven cell lines and
found preferential use of P2 and the splicing pathway
generating the 139 amino acid isoform and suggested that use
of P1 and P3 and the 173 and 141 amino acid isoform
splicing pathways may be regulated in a cell line-regulated
manner. A similar use of P2 and the 139 amino acid isoform
splicing pathway was observed in normal human amnion
(Brandt et al., 1992). We have undertaken a more extensive
study using RT-PCR with exon-specific primers to cover
every promoter and 3' splicing choice and obtained multiple
examples of each tumour type. We and others havePTriP g*ma nMA
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previously identified PTHrP mRNA or protein in human
breast, renal, lung, oesophageal and liver tumours, normal
thyroid and kidney and in parathyroid hyperplasia and
adenoma by Northern blot analysis. RT-PCR, or immuno-
histochemistry (Mangin et al., 1988a, 1989; Ikeda et al., 1988;
Danks et al.. 1989, 1990; Southby et al., 1990; Campos et al..
1992). Immunohistochemical staining for PTHrP in breast.
renal and lung tumours was mostly confined to the tumour
cells, with only occasional staining observed in the stroma or
in blood vessels (Danks et al.. 1989, 1990; Southby et al..
1990), thus indicating that the PTHrP mRNA detected in
this study is most likely to be tumour derived. We found that
each group of tumours exhibited an array of different splic-
ing patterns. Each of the samples examined contained PTHrP
mRNA. Alternative 3' splicing results in the production of
PTHrP isoforms of 139, 173 and 141 amino acids, depending
on whether exon VII, VIII or IX, respectively, is incor-
porated as the 3' exon. Splicing of exon VI to exon IX was
evident in all tissue samples and splicing of exon VI to exon
VII occurred in all but two samples, suggesting that the 141
and 139 amino acid isoforms are common. The exon VIII
splicing pathway. and hence the 173 amino acid isoform, was
less often present. PTHrP gene transcription may be initiated
from three promoters: P1, the upstream TATA promoter, P2.
the GC-rich promoter 5' to exon III and P3, the downstream
TATA promoter. Each of the tissue and tumour samples
contained P3-initiated transcripts, indicating widespread use
of P3, but the use of P1 and P2 was more limited. Hence,
while all samples used P3 and exon IX, there was differential,
however not tissue-specific, use of P1 and P2 and the alterna-
tive exon VIII. This data contradicts that of Brandt et al.
(1994) who suggested that the GC-rich promoter, P2, is the
most active promoter. These studies were performed on RNA
extracted from only seven cell lines and it may be that results
from cell lines cannot readily be extrapolated to primary
tumours. Mangin et al. (1989) observed different 3' splicing
patterns amongst four different tumour types; however only
one sample of each type was studied. In studying a larger
number of tumours we found that different splicing patterns
were utilised within a group of tumours of the same type and
could not demonstrate tissue- or tumour-specific splicing pat-
terns and, by inference, we cannot predict that there are
tissue- or tumour-specific isoforms of PTHrP.
In a number of cases. normal and tumour tissue were
obtained from the same patient. In each case where the
splicing patterns differed, there was an increase in the
number of promoters used and. in two cases, there was also
an increase in the number of 3' splicing pathways utilised in
some lung tumour samples. compared with the normal tissue.
This is perhaps a result of altered regulation as a conse-
quence of transformation to the cancer state and suggests a
general increase in PTHrP transcription in the tumour cells
which possibly contributes to the overexpression of PTHrP in
those tumours which cause hypercalcaemia.
Identification of PTH/'PTHrP receptor mRNA in the nor-
mal kidney and renal tumours was expected, given that the
kidney is one of the targets of PTH action. Breast and lung
are not classical sites of PTH action. however PTH tPTHrP
receptor mRNA has been detected in many rat tissues, in-
cluding breast and lung (Urena et al.. 1993). Since PTHrP
has been detected in vascular smooth muscle (de Papp and
Stewart, 1993) and shown to induce vascular relaxation
(Winquist et al., 1987) it is possible that the PTH 'PTHrP
receptor mRNA detected is denrved from the blood vessels of
the tissues. However if the PTH PTHrP receptor is present in
the same tissues which produce PTHrP it suggests that if the
PTHrP is secreted it may potentially act on the same cell or
neighbounrng cells. possibly affecting the growth and
differentiation of the tumour.
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